MXPA06003646A - Composicion farmaceutica de multi-particulas que comprende acido micofenolico o micofenolato de sodio y combinacion con rapamicina. - Google Patents

Composicion farmaceutica de multi-particulas que comprende acido micofenolico o micofenolato de sodio y combinacion con rapamicina.

Info

Publication number
MXPA06003646A
MXPA06003646A MXPA06003646A MXPA06003646A MXPA06003646A MX PA06003646 A MXPA06003646 A MX PA06003646A MX PA06003646 A MXPA06003646 A MX PA06003646A MX PA06003646 A MXPA06003646 A MX PA06003646A MX PA06003646 A MXPA06003646 A MX PA06003646A
Authority
MX
Mexico
Prior art keywords
rapamycin
salt
layer
composition
prodrug
Prior art date
Application number
MXPA06003646A
Other languages
English (en)
Spanish (es)
Inventor
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA06003646A publication Critical patent/MXPA06003646A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA06003646A 2003-10-03 2004-10-01 Composicion farmaceutica de multi-particulas que comprende acido micofenolico o micofenolato de sodio y combinacion con rapamicina. MXPA06003646A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds
PCT/EP2004/010998 WO2005034916A1 (en) 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin

Publications (1)

Publication Number Publication Date
MXPA06003646A true MXPA06003646A (es) 2006-06-05

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06003646A MXPA06003646A (es) 2003-10-03 2004-10-01 Composicion farmaceutica de multi-particulas que comprende acido micofenolico o micofenolato de sodio y combinacion con rapamicina.

Country Status (11)

Country Link
US (1) US20070036857A1 (enExample)
EP (1) EP1670437A1 (enExample)
JP (1) JP2007507458A (enExample)
AR (1) AR045957A1 (enExample)
AU (1) AU2004280078B2 (enExample)
BR (1) BRPI0414864A (enExample)
CA (1) CA2538099A1 (enExample)
MX (1) MXPA06003646A (enExample)
PE (1) PE20050755A1 (enExample)
TW (1) TW200520759A (enExample)
WO (1) WO2005034916A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472341C (en) 2002-02-01 2011-06-21 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
CN101583347A (zh) * 2006-11-14 2009-11-18 阿里亚德医药股份有限公司 口服制剂
EP2187872A4 (en) * 2007-08-13 2013-09-18 Panacea Biotec Ltd EXTENDED RELEASE COMPOSITIONS COMPRISING SODIUM MYCOPHENOLATE AND METHODS RELATING THERETO
EP2262483A2 (en) * 2008-03-05 2010-12-22 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
EP2446027A1 (en) * 2009-06-25 2012-05-02 Danisco A/S Protein
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
ES2663744T3 (es) * 2011-10-06 2018-04-16 Novartis Ag Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
CA2885979A1 (en) * 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US11633378B2 (en) * 2017-03-13 2023-04-25 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
WO2023119037A1 (en) * 2021-12-23 2023-06-29 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
WO2023224914A1 (en) * 2022-05-16 2023-11-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
DK0721335T3 (da) * 1993-10-01 2006-01-09 Roche Palo Alto Llc Orale suspensioner med höj dosis af mycophenolat-mofetil
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
EP0952820A1 (en) * 1996-10-14 1999-11-03 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU4565000A (en) * 1999-05-10 2000-11-21 Novartis Ag Organic compounds
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
CA2472198A1 (en) * 2002-01-10 2003-07-17 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20070036857A1 (en) 2007-02-15
WO2005034916A1 (en) 2005-04-21
AU2004280078A1 (en) 2005-04-21
PE20050755A1 (es) 2005-11-28
EP1670437A1 (en) 2006-06-21
JP2007507458A (ja) 2007-03-29
BRPI0414864A (pt) 2006-11-28
AR045957A1 (es) 2005-11-16
AU2004280078B2 (en) 2008-08-07
CA2538099A1 (en) 2005-04-21
TW200520759A (en) 2005-07-01

Similar Documents

Publication Publication Date Title
AU2004280078B2 (en) Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin
RU2381026C2 (ru) Фармацевтические композиции, содержащие микофенольную кислоту или ее соль (микофенолят)
AU2008288106B2 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
US20080206322A1 (en) Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin
AU2002338897A1 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
JP2011513498A (ja) 弱塩基性薬物と有機酸とを含む薬物送達システム
HK1253034A1 (zh) 包含urat1的有效抑制剂的药物组合物
WO2009047799A1 (en) High dose solid unit oral pharmaceutical dosage form of mycophenolate sodium and process for making same
CA2578375A1 (en) Vaccine immunotherapy for immune suppressed patients
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
EP3166599B1 (en) Capsule dosage form of metoprolol succinate
CN1863509A (zh) 包含麦考酚酸或麦考酚酸钠的多粒子药物组合物和与雷帕霉素的组合
MXPA06004017A (es) Formas de dosis una vez al dia de trospio
HK1067861B (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt

Legal Events

Date Code Title Description
FA Abandonment or withdrawal